Olfactory deficits have been observed in subjects with Alzheimer’s disease (AD) and its potential as a biomarker has been demonstrated by several recent studies. However, its sensitivity and specificity in detecting early AD have not been validated in the Chinese population where aging population is growing rapidly. In this study, by using a 3.0 T MR scanner, we evaluate the presence of olfactory deficits and hippocampal volume loss measured by FreeSurfer (6.0) based on local population in China, to validate the use of olfactory test battery as a clinical AD marker.
This abstract and the presentation materials are available to members only; a login is required.